DETAILED ACTION
Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
Amendment
This office action is responsive to the amendment filed on 9/11/26. As directed by the amendment: claims 1-4, 9-11, 17, 20-22, 27, 29 and 34 have been amended, no claims have been canceled, and no new claims have been added. Thus, claims 1-36 are presently pending in the application.
Claim Rejections - 35 USC § 103
In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status.
The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action:
A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made.
Claims 1-3, 5-6, 9-10 and 14-17 are rejected under 35 U.S.C. 103 as being unpatentable over Tolmie et al. (2007/0181126) in view of Richardson (5,752,506), Bathe et al. (6,581,592) and Krishnan et al. (2007/0224708).
Regarding claim 1, in fig. 1 Tolmie discloses a method of delivering nitric oxide gas to a patient in need thereof, the method comprising: providing, through at least one control valve 37 of a nitric oxide delivery system, a flow of nitric oxide gas 38 to an injector 36 for introducing the nitric oxide gas into a breathing gas (16 and 18) in an inspiratory limb (tubing just downstream of 36, or 32) of a breathing circuit (structure in fig. 1) affiliated with a ventilator (12 [0018]); measuring, using at least one NO flow sensor 39, NO flow, wherein the at least one NO flow sensor is in fluid communication with a therapeutic gas inlet (where arrow that points to 36 is located) of the injector; receiving, using a control system 52 in communication with the at least one NO flow sensor (Fig. 1), flow information from the at least one NO flow sensor ([0035] fig. 1); and delivering the nitric oxide gas to the patient (14, abstract), but is silent regarding that the ventilator is a high frequency ventilator or ventilation techniques which provide reverse and/or oscillations in inspiratory pressure or flow. However, Richardson teaches a breathing circuit is affiliated with a high frequency ventilator or ventilation techniques which provide reverse and/or oscillations in inspiratory pressure or flow (Col. 6, ll. 44-47) in addition to nitric oxide delivery (Col. 6, ll. 50-55). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify Tolmie’s ventilation with high frequency ventilation, as taught by Richardson, for the purpose of providing an alternate ventilation modality depending on the particular patient having the predictable results of ventilating a patient (Col. 1, ll. 18-20 Richardson). The modified Tolmie is silent regarding that the flow information comprising closed-valve flow information generated while the control valve is closed; and determining, based at least in part on the closed-valve flow information, whether the flow of nitric oxide gas is leaking past the control valve. However, in fig. 1 Bathe teaches an NO flow sensor 40 is downstream of the control valve 30 in the nitric oxide delivery system and in fig. 1 Krishnan teaches that the flow information comprising closed-valve flow information generated while the control valve 102 is closed [0027]; and determining, based at least in part on the closed-valve flow information, whether the flow of nitric oxide gas is leaking past the control valve [0027]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Tolmie’s NO flow sensor and control valve with the NO flow sensor downstream of the control valve and flow information with closed-valve flow information, as taught by Bathe and Krishnan, for the purpose of providing an alternate configuration having the predictable results of determining NO flow to control the control valve and for determining if a leak is present in the control valve.
Regarding claim 2, the modified Tolmie discloses that the injector module has an injector body (body of 36, Tolmie) having a first opening (opening that 28 connects to, Tolmie) and a second opening (opening closer to 40, Tolmie), the first opening and the second opening for coupling the injector to the inspiratory limb (conduit just downstream of 36, Tolmie) of the breathing circuit enabling the breathing gas in the breathing circuit to flow through the first opening and the second opening (Fig. 1, Tolmie).
Regarding claim 3, the modified Tolmie discloses that the therapeutic gas inlet is in the injector body (Fig. 1, Tolmie), wherein the therapeutic gas inlet receives the flow of the nitric oxide gas (Fig. 1, Tolmie) and enable injection of the nitric oxide gas into the injector (Fig. 1, Tolmie), and subsequently into the breathing gas in the inspiratory limb of the breathing circuit (Fig. 1, Tolmie).
Regarding claim 5, the modified Tolmie discloses that the therapeutic gas inlet receives the flow of nitric oxide gas from a nitric oxide source 38, via a conduit (conduit leading to 36 from 38, Tolmie).
Regarding claim 6, the modified Tolmie discloses that the nitric oxide source is a cylinder storing NO ([0021] Tolmie, fig. 1) or an NO generator.
Regarding claim 9, the modified Tolmie discloses that monitoring the flow information, using the control system, to ensure that a desired dose of NO is delivered into the injector, and subsequently into the breathing gas in the inspiratory limb of the breathing circuit ([0028] Tolmie).
Regarding claim 10, the modified Tolmie discloses that monitoring the flow information using the control system to ensure a desired dose of NO is not under delivered and/or under dosed ([0028] Tolmie).
Regarding claim 14, the modified Tolmie discloses that the inspiratory limb (32 receives both inspiration and expiration, Tolmie) is also an expiratory limb in the breathing circuit.
Regarding claim 15, the modified Tolmie disclsoes that the NO flow sensor is downstream of the control valve in the nitric oxide delivery system (NO flow sensor 40 is downstream of the control valve 30, Fig. 1 Bathe).
Regarding claim 16, the modified Tolmiediscloses that the control valve is upstream of the NO flow sensor in the nitric oxide delivery system (NO flow sensor 40 is downstream of the control valve 30, Fig. 1 Bathe).
Regarding claim 17, the modified Tolmie discloses that receiving the flow of nitric oxide gas at the therapeutic gas inlet (where arrow meets 36, Tolmie) via a conduit (conduit that meets 36 at arrow, Tolmie), wherein the conduit has one or more of (i) an internal cross-sectional diameter of 1/32 of an inch to 1/4 of an inch and (ii) an internal portion (conduit within 50, Tolmie) within the nitric oxide delivery system (50, Tolmie) and an external portion (conduit outside of 50, Tolmie) outside the nitric oxide delivery system, the internal portion of the conduit having a cross-sectional diameter that is the same as a cross-sectional diameter of the external portion of the conduit (Fig. 1, Tolmie).
Claim 12-13 are rejected under 35 U.S.C. 103 as being unpatentable over Tolmie, Richardson, Bathe and Krishnan, as applied to claim 1 above, in further view of Sansom (2014/0358022).
Regarding claim 12, the modified Tolmie is silent regarding that the at least one NO flow sensor is at least one bi-directional flow sensor. However, in fig. 5 Sansom teaches a flow sensor is at least one bi-directional flow sensor (using a bi-directional constant temperature anemometry flow sensor [0005][0039]). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Tolmie’s NO flow sensor with a bi-directional constant temperature anemometry flow sensor, as taught by Sansom, for the purpose of providing an alternate flow sensor having the predictable results of determining flow as well as the advantage of determining the direction of flow with reduced dead space and weight ([0005] Sansom).
Regarding claim 13, the modified Tolmie discloses that the at least one bi-directional flow sensor is a thermal mass flow meter ([0005][0039] Sansom) or a thermal dispersion flow meter.
Claims 7-8 are rejected under 35 U.S.C. 103 as being unpatentable over Tolmie, Richardson, Bathe and Krishnan, as applied to claim 6 above, in further view of Rounbehler et al. (2006/0180147).
Regarding claim 7, the modified Tolmie is silent regarding generating the nitric oxide gas by reaction of a NO-releasing agent with a reductant using the NO generator. However, Rounbehler teaches generating the nitric oxide gas by reaction of a NO-releasing agent with a reductant using the NO generator (abstract). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Tolmie’s NO gas container with an NO gas generator, as taught by Rounbehler, for the purpose of providing an alternate source of nitric oxide having the predictable results of providing nitric oxide to a user for respiratory therapy.
Regarding claim 8, the modified Tolmie discloses that the NO-releasing agent is nitrogen dioxide and the reductant is ascorbic acid (abstract Rounbehler).
Claim 11 is rejected under 35 U.S.C. 103 as being unpatentable over Tolmie, Richardson, Bathe and Krishnan, as applied to claim 1 above, in further view of Jamison (2010/0175695).
Regarding claim 11, the modified Tolmie is silent regarding opening or closing a check valve that is one or more of (i) in fluid communication with the therapeutic gas inlet of the injector module and (ii) is integral to the injector module. However, in fig. 2 Jamison teaches opening or closing a check valve 246 that is one or more of (i) in fluid communication with a therapeutic gas inlet of the injector module 236 and (ii) is integral to the injector module 236. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Tolmie’s inhalation limb with the addition of a check valve, as taught by Jamison, for the purpose of preventing backflow.
Claim 18 is rejected under 35 U.S.C. 103 as being unpatentable over Tolmie, Richardson, Bathe and Krishnan, as applied to claim 1 above, in further view of Hu et al. (5,939,618).
Regarding claim 18, the modified Tolmie is silent regarding measuring, using at least a second NO flow sensor, NO flow, wherein the second NO flow sensor is in fluid communication with the therapeutic gas inlet and in communication with the control system, receiving, at the control system, flow information from the second NO flow sensor; and detecting, using the control system, a leak when the flow information from the NO flow sensors does not match. However, in fig. 1 Hu teaches measuring, using a first 22 and second 26 flow sensor, wherein first and second flow sensors are in fluid communication with a therapeutic gas inlet 18 and in communication with the control system (Col. 5, ll. 15-21), receiving, at the control system, flow information from the first and second flow sensors (Col. 5, ll. 15-21); and detecting, using the control system, a leak when the flow information from the NO flow sensors does not match (Col. 5, ll. 22-25). It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Tolmie’s NO flow sensor with the addition of a second NO flow sensor, as taught by Hu, for the purpose of determining if a leak occurs.
Claim 19 is rejected under 35 U.S.C. 103 as being unpatentable over Tolmie, Richardson, Bathe, Krishnan and Hu, as applied to claim 18 above, in further view of Nightingale et al. (2013/0133656).
Regarding claim 19, the modified Tolmie is silent regarding increasing the flow of nitric oxide gas if a leak is detected. However, Nightingale teaches increasing gas flow if a leak is detected [0144]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the modified Tolmie’s gas flow with increased gas flow if a leak is detected, as taught by Nightingale, for the purpose of compensating for the lost flow due to leakage.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b).
The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13.
The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer.
Claims 1 and 4 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 1 of U.S. Patent No. 10,835,696 in view of Krishnan et al. (2007/0224708). The instant claims recite the features in patented claim 1 except that the flow information comprising closed-valve flow information generated while the control valve is closed; and determining, based at least in part on the closed-valve flow information, whether the flow of nitric oxide gas is leaking past the control valve. However, in fig. 1 Krishnan teaches that the flow information comprising closed-valve flow information generated while the control valve 102 is closed [0027]; and determining, based at least in part on the closed-valve flow information, whether the flow of nitric oxide gas is leaking past the control valve [0027]. It would have been obvious to one of ordinary skill in the art before the effective filing date of the claimed invention to modify the patented claim 1’s NO flow sensor and control valve with flow information with closed-valve flow information, as taught by Krishnan, for the purpose of providing an alternate configuration having the predictable results of determining NO flow to control the control valve and for determining if a leak is present in the control valve.
Dependent claim 5 is covered by patented claim 7.
Dependent claim 9 is covered by patented claim 3.
Dependent claim 10 is covered by patented claim 4.
Dependent claim 11 is covered by patented claim 5.
Dependent claim 15-16 is covered by patented claim 6.
Dependent claim 17 is covered by patented claim 7.
Dependent claim 18 is covered by patented claim 8.
Dependent claim 19 is covered by patented claim 9.
Claims 20 and 23 are rejected on the ground of nonstatutory double patenting as being unpatentable over claim 10 of U.S. Patent No. 10,835,696. Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claim is broader than the patented claim (i.e. the patented claim 10 recites “forward flow information and reverse flow information,” which is language not found in instant claim 20). Therefore, any infringement over patented claim would result in infringement over instant claims.
Dependent claim 27 is covered by patented claim 13.
Dependent claim 28 is covered by patented claim 14.
Dependent claim 29 is covered by patented claim 15.
Dependent claims 32-33 are covered by patented claim 17.
Dependent claim 34 is covered by patented claim 18.
Response to Arguments
Applicant’s arguments, see pages 10-12, filed 9/11/26, with respect to the rejection of claim 1 under Tolmie et al. (2007/0181126) in view of Richardson (5,752,506) have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Tolmie et al. (2007/0181126) in view of Richardson (5,752,506), Bathe et al. (6,581,592) and Krishnan et al. (2007/0224708).
Applicant’s arguments with respect to claims 4 and 20-36 have been fully considered and are persuasive. The 103 rejections of claims 4 and 20-36 have been withdrawn.
Conclusion
Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).
A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.
Any inquiry concerning this communication or earlier communications from the examiner should be directed to RACHEL T SIPPEL whose telephone number is (571)270-1481. The examiner can normally be reached M-F 9:00-5:00 PM.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Timothy Stanis can be reached at (571) 272-5139. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.
/RACHEL T SIPPEL/Primary Examiner, Art Unit 3785